



Entheon Biomedical Announces Share Consolidation

VANCOUVER, BC, February 21, 2024 – Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**") announces that the Board of Directors has approved a consolidation of all of the Company's issued and outstanding common shares on the basis of ten (10) pre-consolidated shares for every one (1) post-consolidated share (the "Consolidation").

After giving effect to the Consolidation, the Company will have 5,908,926 common shares issued and outstanding. The Company's name and stock symbol shall remain the same.

The Consolidation remains subject to the approval of Canadian Securities Exchange. The Company will issue a further news release announcing the effective date in which the Company will commence trading on a consolidated basis.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

<https://entheonbiomedical.com>